Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemoradiotherapy
/ methods
Combined Modality Therapy
Female
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Induction Chemotherapy
/ methods
Male
Middle Aged
Neoplasm Recurrence, Local
/ prevention & control
Otorhinolaryngologic Neoplasms
/ diagnostic imaging
Otorhinolaryngologic Surgical Procedures
Positron Emission Tomography Computed Tomography
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Head and neck squamous cell carcinoma (HNSCC)
Induction chemotherapy
Resection
Single-cycle
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
14
05
2019
accepted:
20
09
2019
pubmed:
5
10
2019
medline:
18
11
2020
entrez:
5
10
2019
Statut:
ppublish
Résumé
The response to induction chemotherapy (IC) predicts local control after conservative treatment of laryngeal, meso- and hypopharyngeal head and neck squamous cell carcinoma (HNSCC) and can thus help to avoid surgery. Single-cycle induction chemotherapy may help to maintain a low local recurrence rate while keeping the overall toxicity manageable. However, long-term data on single-cycle IC response by tumor location is lacking. N = 102 patients with functionally inoperable primary HNSCC of the larynx (n = 43), hypopharynx (n = 42) or mesopharynx/tongue (n = 17) received one cycle of docetaxel (75 mg/m The overall response rate was 72.5%. All 74 responders and 10 non-responders received primary CRT, and 18 patients received primary surgery after single-cycle IC. Overall 10-year local recurrence-free survival (LRFS) was 73.7%. Three-year LRFS was 88.2% (mesopharynx/tongue), 88.2% (larynx), and 73.3% (hypopharynx); p = 0.17. 3-year distant metastasis-free survival (DMFS) was 94.1% (mesopharynx/tongue), 88.0% (larynx) and 76.4% (hypopharynx); p > 0.05. This influenced the 3-year cancer-specific survival (CSS) for larynx (91.2%) vs. hypopharynx tumors (60.8%); p = 0.003, but CSS was not different to tumors in the mesopharynx/tongue (81.4%); p > 0.05. A single-cycle induction chemotherapy for HNSCC enables surgery plus adjuvant therapy as well as chemoradiotherapy. The long-term local and distant disease control was good but varied between tumors in the larynx and mesopharynx/tongue vs. hypopharynx.
Identifiants
pubmed: 31583430
doi: 10.1007/s00405-019-05665-5
pii: 10.1007/s00405-019-05665-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-254Références
Budach W, Bölke E, Kammers K et al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol 118:238–243
doi: 10.1016/j.radonc.2015.10.014
Geoffrois L, Martin L, De Raucourt D et al (2018) Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. https://doi.org/10.1200/JCO.2017.76.2591 (In press)
doi: 10.1200/JCO.2017.76.2591
pubmed: 30016178
Ensley JF, Jacobs JR, Weaver A et al (1984) Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54:811–814
doi: 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E
Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852
doi: 10.1200/JCO.2012.43.6097
Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704
doi: 10.1056/NEJMoa071028
Dietz A, Wichmann G, Kuhnt T et al (2018) Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 29:2105–2114
doi: 10.1093/annonc/mdy332
Worden FP, Kumar B, Lee JS et al (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138–3146
doi: 10.1200/JCO.2007.12.7597
Urba S, Wolf G, Eisbruch A et al (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24:593–598
doi: 10.1200/JCO.2005.01.2047
Semrau S, Waldfahrer F, Lell M et al (2011) Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol 187:15–22
doi: 10.1007/s00066-010-2178-2
Dos Anjos RF, Dos Anjos DA, Vieira DL et al (2016) Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: a systematic review. Medicine (Baltimore) 95:e4450. https://doi.org/10.1097/MD.0000000000004450
doi: 10.1097/MD.0000000000004450
Kuhnt T, Becker A, Bloching M et al (2006) Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors. Med Oncol 23:325–333
doi: 10.1385/MO:23:3:325
Lefebvre JL, Andry G, Chevalier D et al (2012) Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23:2708–2714
doi: 10.1093/annonc/mds065
Cohen EE, Karrison TG, Kocherginsky M et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32:2735–2743
doi: 10.1200/JCO.2013.54.6309
Haddad R, O'Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264
doi: 10.1016/S1470-2045(13)70011-1
Lefebvre JL, Pointreau Y, Rolland F et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 31:853–859
doi: 10.1200/JCO.2012.42.3988
Kufeldt J, Viehrig M, Schweikert D et al (2018) Treatment of malnutrition decreases complication rates and shortens the length of hospital stays in a radiation oncology department. Strahlenther Onkol 194:1049–1059
doi: 10.1007/s00066-018-1360-9
Ursino S, Cocuzza P, Seccia V et al (2018) Pattern of dysphagia after swallowing-sparing intensity-modulated radiotherapy (IMRT) of head and neck cancers: results of a mono-institutional prospective study. Strahlenther Onkol 194:1114–1123
doi: 10.1007/s00066-018-1328-9
Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506
doi: 10.1093/jnci/djp007
Modesto A, Galissier T, Lusque A et al (2019) Definitive radiochemotherapy or initial surgery for oropharyngeal cancer: to what extent can p16 expression be used in the decision process? Strahlenther Onkol. https://doi.org/10.1007/s00066-019-01451-8
doi: 10.1007/s00066-019-01451-8
pubmed: 30877351
Fietkau R, Iro H, Hecht M et al (2017) Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum. J Clin Oncol 35(15_suppl):6016–6016
doi: 10.1200/JCO.2017.35.15_suppl.6016